首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Comparative Clinical Observation of Arthroscopic Microfracture in the Presence and Absence of a Stromal Vascular Fraction Injection for Osteoarthritis
【2h】

Comparative Clinical Observation of Arthroscopic Microfracture in the Presence and Absence of a Stromal Vascular Fraction Injection for Osteoarthritis

机译:关节镜微骨折在有无基质血管分数注射治疗骨关节炎中的比较临床观察

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Osteoarthritis (OA) is a degenerative cartilage disease that is characterized by a local inflammatory reaction. Consequently, many studies have been performed to identify suitable prevention and treatment interventions. In recent years, both arthroscopic microfracture (AM) and stem cell therapy have been used clinically to treat OA. This study aimed to evaluate the clinical effects of AM in the presence and absence of a stromal vascular fraction (SVF) injection in the management of patients with OA. Thirty patients with grade 2 or 3 (Lawrence scale) OA of the knee participated in this study. Placebo group patients (n = 15) received AM alone; treatment group patients (n = 15) received AM and an adipose tissue‐derived SVF injection. The SVF was suspended in platelet‐rich plasma (PRP) before injection into the joint. Patient groups were monitored and scored with the Western Ontario and McMaster Universities Arthritis Index (WOMAC), Lysholm, Visual Analog Pain Scale (VAS), and modified Outerbridge classifications before treatment and at 6, 12, and 18 months post‐treatment. Bone marrow edema was also assessed at these time points. Patients were evaluated for knee activity (joint motion amplitude) and adverse effects relating to surgery and stem cell injection. Treatment efficacy was significantly different between placebo and treatment groups. All treatment group patients had significantly reduced pain and WOMAC scores, and increased Lysholm and VAS scores compared with the placebo group. These findings suggest that the SVF/PRP injection efficiently improved OA for 18 months after treatment. This study will be continuously monitored for additional 24 months. Stem Cells Translational Medicine 2017;6:187–195
机译:骨关节炎(OA)是一种软骨退行性疾病,其特征在于局部炎症反应。因此,已经进行了许多研究来确定合适的预防和治疗干预措施。近年来,关节镜微骨折(AM)和干细胞疗法已在临床上用于治疗OA。这项研究旨在评估在存在和不存在间质血管分数(SVF)注射剂的情况下AM对OA患者的管理的临床效果。 30名膝关节OA 2级或3级(劳伦斯氏量表)的患者参加了这项研究。安慰剂组患者(n = 15)仅接受AM治疗;治疗组患者(n = 15)接受AM和脂肪组织来源的SVF注射。 SVF在注入关节之前先悬浮在富含血小板的血浆(PRP)中。在治疗前以及治疗后6、12和18个月,对患者组进行监测并用西安大略省和麦克马斯特大学关节炎指数(WOMAC),Lysholm,视觉模拟疼痛量表(VAS)以及改良的外桥分类进行评分。在这些时间点还评估了骨髓水肿。对患者的膝关节活动(关节运动幅度)以及与手术和干细胞注射有关的不良反应进行了评估。安慰剂组和治疗组之间的治疗效果显着不同。与安慰剂组相比,所有治疗组患者的疼痛和WOMAC评分均明显降低,Lysholm和VAS评分均升高。这些发现表明,SVF / PRP注射治疗后18个月可有效改善OA。这项研究将继续持续监测24个月。干细胞转化医学2017; 6:187–195

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号